We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

OGT Launches New Arrays for Developmental Disorders at ESHG

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Oxford Gene Technology (OGT) have launched a new range of arrays at the European Society of Human Genetics (ESHG) Conference in Glasgow, UK, that are dedicated to elucidating the underlying causes of developmental delay. OGT’s unique Cytosure™ Constitutional v3 arrays have been developed following its recent licence agreement with the Wellcome Trust Sanger Institute to access the Deciphering Developmental Disorders  (DDD) study data — which successfully identified new areas of the genome responsible for developmental disorders.1, 2 OGT has used this data, together with the latest updates from ClinGen*, to deliver the most advanced, high-resolution developmental disorder arrays currently available. 

OGT has optimised the arrays via a proprietary probe design algorithm and experimental validation, enabling the selection of highly-targeted, specific probes throughout the genome. Using an informed, sophisticated approach to array design, more of these optimised probes have been placed in regions of the genome that are most likely to detect a biologically relevant aberration. The result of this careful design procedure means that regions with the highest priority are covered at exon-level resolution on the arrays, enabling single-exon CNV detection in up to 502 prioritised genes of interest.

CytoSure_OGT.jpg

James Clough, Executive Vice President Commercial at OGT commented, “Through combining our superior array design capabilities with the latest research-led gene content, we are proud to offer our customers the most advanced array design available for accurately and easily identifying the causal aberrations underlying developmental delay. These new products underline OGT’s long-standing commitment to providing cytogenetics researchers with the latest tools to further understand developmental disorders”. 

Providing straightforward analysis, all CytoSure arrays come with OGT’s renowned Cytosure Interpret Software and full on-site training, streamlining data analysis and interpretation. Innovative features enable the automation of data analysis workflows, minimising user intervention and maximising both consistency and speed of interpretation. 

Find out more about the most advanced arrays for identifying developmental disorders at www.ogt.com.  

* Formerly ISCA/ICCG.

References

1. Large-scale discovery of novel genetic causes of developmental disorders. The Deciphering Developmental Disorders Study. Fitzgerald, T.W. et al, Nature 519, 223–228 (12 March 2015) 
2. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Fitzgerald, T.W. et al,  The Lancet 385, No. 9975, p1305–1314, (4 April 2015)